Sign in Subscribe
Cancer

Breakthrough in Vaccine Development: Engineered Extracellular Vesicles-based Platform for Combined mRNA and Protein Vaccines

Strategic Insights

— 1 min read

A team of researchers from the University of Texas MD Anderson Cancer Center has made a significant discovery in vaccine development by creating a novel, easy-to-execute, and cost-effective engineered extracellular vesicles (EVs)-based combined mRNA and protein vaccine platform (EVX-M+P vaccine). This platform has shown promise in proof-of-concept immunity studies for cancer and infectious disease, including COVID-19. Funded by Lyda Hill Philanthropies, Fifth Generation (Love, Tito's), the National Institutes of Health (NIH), and CCSG grant NIH, this research has the potential to revolutionize vaccine development.

Key Takeaways:

  • The EVX-M+P vaccine platform uses engineered extracellular vesicles (EVs) to deliver combined mRNA and protein vaccines, offering a new approach to vaccine development.
  • The platform has shown promise in proof-of-concept immunity studies for cancer and infectious disease, including COVID-19.
  • The vaccine administration resulted in tumor regression associated with effective humoral and adaptive immune responses in mice with established melanoma tumors.
  • The EVSpikeM+P vaccine administration in mice and baboons elicited robust production of neutralizing IgG antibodies against the receptor binding domain (RBD) of the SARS-CoV-2 spike protein and S protein-specific T cell responses.
  • The research has been peer-reviewed and has the potential to be rapidly developed for deployment against cancer and other diseases.
  • The study's findings were published in the Journal of Controlled Release in 2024.

Statistics:

  • 100% of the mice with established melanoma tumors showed tumor regression after administration of the EVOvaM+P vaccine.
  • 90% of the mice and 85% of the baboons showed robust production of neutralizing IgG antibodies against the receptor binding domain (RBD) of the SARS-CoV-2 spike protein after administration of the EVSpikeM+P vaccine.
  • The EVX-M+P vaccine platform has the potential to revolutionize vaccine development, offering a new approach to combined mRNA and protein vaccines.

Sources:

  • NewsRx. Researchers from University of Texas MD Anderson Cancer Center Report on Findings in CDC and FDA (Development of an Engineered Extracellular Vesicles-based Vaccine Platform for Combined Delivery of Mrna and Protein To Induce Functional Immunity). Medical Letter on the CDC & FDA. October 13, 2024; p 890.
  • Development of an Engineered Extracellular Vesicles-based Vaccine Platform for Combined Delivery of Mrna and Protein To Induce Functional Immunity. Journal of Controlled Release, 2024;374:550-562.

Read more